Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

274 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group.
Le Cesne A, Judson I, Crowther D, Rodenhuis S, Keizer HJ, Van Hoesel Q, Blay JY, Frisch J, Van Glabbeke M, Hermans C, Van Oosterom A, Tursz T, Verweij J. Le Cesne A, et al. Among authors: tursz t. J Clin Oncol. 2000 Jul;18(14):2676-84. doi: 10.1200/JCO.2000.18.14.2676. J Clin Oncol. 2000. PMID: 10894866 Clinical Trial.
Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Steward WP, Verweij J, Somers R, Spooner D, Kerbrat P, Clavel M, Crowther D, Rouesse J, Tursz T, Tueni E, et al. Steward WP, et al. Among authors: tursz t. J Clin Oncol. 1993 Jan;11(1):15-21. doi: 10.1200/JCO.1993.11.1.15. J Clin Oncol. 1993. PMID: 8418226
Liver metastases from extremity soft tissue sarcoma.
Merimsky O, Terrier P, Stanca A, Le Chevalier T, Spielmann M, Tursz T, Le Cesne A. Merimsky O, et al. Among authors: tursz t. Am J Clin Oncol. 1999 Feb;22(1):70-2. doi: 10.1097/00000421-199902000-00017. Am J Clin Oncol. 1999. PMID: 10025385
Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
Van Glabbeke M, van Oosterom AT, Oosterhuis JW, Mouridsen H, Crowther D, Somers R, Verweij J, Santoro A, Buesa J, Tursz T. Van Glabbeke M, et al. Among authors: tursz t. J Clin Oncol. 1999 Jan;17(1):150-7. doi: 10.1200/JCO.1999.17.1.150. J Clin Oncol. 1999. PMID: 10458228
[Soft tissue sarcomas: general review].
Fizazi K, Cojean I, Le Cesne A, Kayitalire L, Le Chevalier T, Tursz T, Spielmann M. Fizazi K, et al. Among authors: tursz t. Bull Cancer. 1994 Oct;81(10):835-52. Bull Cancer. 1994. PMID: 7734766 Review. French.
The use of recombinant human granulocyte-macrophage colony-stimulating factor with combination chemotherapy in the treatment of advanced adult soft-tissue sarcomas: early results from the EORTC Soft-Tissue and Bone Sarcoma Group.
Steward WP, Verweij J, Somers R, Spooner D, Kerbrat P, Clavel M, Crowther D, Rouesse J, Tursz T, Tueni E, et al. Steward WP, et al. Among authors: tursz t. Cancer Chemother Pharmacol. 1993;31 Suppl 2:S241-4. Cancer Chemother Pharmacol. 1993. PMID: 8453707
High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group.
Nielsen OS, Dombernowsky P, Mouridsen H, Crowther D, Verweij J, Buesa J, Steward W, Daugaard S, van Glabbeke M, Kirkpatrick A, Tursz T. Nielsen OS, et al. Among authors: tursz t. Br J Cancer. 1998 Dec;78(12):1634-9. doi: 10.1038/bjc.1998.735. Br J Cancer. 1998. PMID: 9862576 Free PMC article. Clinical Trial.
274 results